Immunocore Holdings plc (IMCR) has a negative trailing P/E of -59.7, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 10.3 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -1.68%, forward earnings yield 9.72%. PEG 0.10 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 56/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -3.7 | 0.00 | 0.49 | 5.23 | - |
| 2017 | -1.6 | -0.01 | 0.58 | 5.54 | - |
| 2018 | -12.9 | 0.14 | 16.34 | 39.09 | - |
| 2019 | -8.6 | -0.19 | 45.46 | 34.65 | - |
| 2020 | -13.6 | 0.35 | 18.16 | 33.37 | - |
| 2021 | -8.1 | -0.23 | 4.64 | 39.74 | - |
| 2022 | -49.6 | 0.71 | 6.36 | 14.95 | - |
| 2023 | -60.0 | 9.50 | 9.00 | 13.31 | - |
| 2024 | -36.1 | -2.47 | 4.09 | 5.95 | - |
| 2025 | -66.1 | 1.38 | 4.59 | 5.87 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2018 | $-2.62 | $23.65M | $-71.63M | -302.8% |
| 2019 | $-3.81 | $25.67M | $-103.93M | -404.9% |
| 2020 | $-2.33 | $30.11M | $-74.09M | -246% |
| 2021 | $-3.00 | $26.52M | $-131.52M | -495.9% |
| 2022 | $-0.90 | $143.74M | $-41.22M | -28.7% |
| 2023 | $-1.13 | $249.43M | $-55.29M | -22.2% |
| 2024 | $-1.02 | $310.2M | $-51.09M | -16.5% |
| 2025 | $-0.53 | $297.57M | $-26.42M | -8.9% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.96 | $-1.51 – $-0.26 | $448.8M | $422.87M – $476.86M | 11 |
| 2027 | $-1.25 | $-9.35 – $2.88 | $488.79M | $418.5M – $532.68M | 10 |
| 2028 | $-0.01 | $-0.05 – $0.04 | $597M | $596.1M – $597.89M | 9 |
| 2029 | $3.08 | $2.53 – $3.55 | $809.77M | $699.21M – $904.83M | 3 |
| 2030 | $6.20 | $5.10 – $7.14 | $1.05B | $908.11M – $1.18B | 3 |
